TrialNature communications2025

Levosimendan for postoperative subclinical heart failure after noncardiac surgery: a randomized, double-blinded, phase III trial.

Christian Reiterer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.